What is EP4374855A1 about, and how does it relate to candesartan + indapamide?
EP4374855A1 is a European patent publication that (based on its title/subject matter) targets a pharmaceutical invention involving candesartan and indapamide, a combination used to treat hypertension. The patent filing sits in the same technical space as other patents that cover formulations, dosing instructions, processes, or specific claims for that fixed-dose combination.
Because a specific “EP4374855A1 candesartan indapamide patent” query usually aims to identify the exact protection scope, the key practical point is that the document’s claims determine what is actually covered—not the drug combination name alone.
How can I find the exact claims and determine what is protected?
To understand whether EP4374855A1 blocks generic or biosimilar-style competition (or only certain manufacturing/formulation methods), you typically look for:
- Claim wording in the publication (the only part that legally matters for infringement analysis).
- Whether it claims a particular formulation (e.g., tablet/capsule composition), particle size, release profile, specific dose ratios, or manufacturing process steps.
- Any dependency structure (some claims are narrower and “depend” on broader ones).
If you paste the claim section (or the “claims” pages) from EP4374855A1, I can translate it into plain English and map it to likely regulatory product concepts (formulation vs. method vs. dosing).
When would a candesartan + indapamide patent like this typically expire in Europe?
In Europe, patent term is generally tied to when the earliest priority date is filed, plus the standard patent duration (commonly 20 years from the earliest priority date), subject to extensions. The publication number itself (EP4374855A1) does not by itself tell you:
- the earliest priority date,
- whether there are valid term extensions,
- or whether the patent is even granted (publication ≠ granted in all cases).
If you share the “priority” dates listed on the front page of EP4374855A1 (or a screenshot/text of that header), the expiry estimate can be calculated precisely.
Does this publication mean there is guaranteed exclusivity against generics?
No. A published application like EP4374855A1 does not automatically mean:
- the patent has been granted,
- the granted claims cover the generic product’s exact formulation/process,
- or that regulatory exclusivity (if any) aligns with the patent’s claim scope.
Generics and follow-on products typically evaluate both:
- patent claim coverage (what is actually infringed), and
- regulatory data/exclusivity periods (separate from patent term).
Is EP4374855A1 likely to be a formulation/process patent rather than a “core compound” patent?
For fixed-dose hypertension combinations such as candesartan + indapamide, later filings often focus on practical improvements, such as:
- specific solid-state form or tablet composition,
- improved stability,
- dissolution or release characteristics,
- or manufacturing methods that support consistent bioavailability.
That pattern matters because many “combination drug” markets rely on different layers of protection: early compound coverage (from the original drug inventions) plus later patents on formulations/dosing/processes.
Can this patent still be challenged, and what would that look like?
Yes. In Europe, challenging coverage typically happens through:
- patent oppositions at the EPO after grant, and/or
- national litigation for infringement/non-infringement.
The common battlefield is whether the generic product:
- falls within the claim boundaries (literally or under claim interpretation), or
- uses a sufficiently different formulation/process so it does not infringe.
What do you need to answer “Is EP4374855A1 relevant to a specific generic product?”
To determine practical relevance, you usually need two pieces of information:
1) EP4374855A1’s specific claim(s) (especially independent claims and any formulation/process limitations).
2) The generic product details (tablet strength, release type, formulation/process disclosures if available, or regulatory documentation describing composition).
If you want, I can look up the document text you provide and summarize it
If you paste any of the following from EP4374855A1, I can produce a tight “what it covers / what it likely blocks / likely expiry timeline” answer:
- the abstract
- the first 1–3 independent claims
- the priority date(s) from the front page
- any mention of dosage/formulation/process in the claims